Who Is the Ideal Patient for SI Fusion? Who Is Not?
Matthew Smuck, MD (Stanford University) and Joshua E. Heller, MD (Thomas Jefferson University) discuss patient selection for sacroiliac dysfunction.
Disclosure:
Heller, Joshua E.: Consulting: Nuvasive (D), Providence Medical Technology (D), SI Bone (C).
Smuck, Matthew: Board of Directors: Spine Intervention Society (None); Consulting: Consultant & expert witness - State Farm (F), Spine Biopharma (Future Compensation Expected); Grants: Relievant Medsystems (F, Paid directly to institution/employer), ReWalk (E, Paid directly to institution/employer); Private Investments: Vivametrica (15.00%); Scientific Advisory Board: BlueJay Mobile-Health (Stock options), NuSpine (Stock options); Stock Ownership: BlueJay Mobile-Health (less than 1%), NuSpine (less than 1%); Trips/Travel: Spine Intervention Society, Board of Directors (B, Travel Expenses).
Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+
Create your
podcast in
minutes
It is Free